Skip to main content
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. — Investor Relations & Filings

Ticker · ELTX ISIN · US03476J1079 US Professional, scientific and technical activities
Filings indexed 348 across all filing types
Latest filing 2026-03-17 Regulatory Filings
Country US United States of America
Listing US ELTX

About Elicio Therapeutics, Inc.

https://elicio.com/

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for cancer treatment. The company utilizes its proprietary Amphiphile (AMP) platform to deliver vaccines, immunomodulators, and adjuvants directly to the lymph nodes. This targeted-delivery approach is designed to bind therapeutic agents to albumin, a protein in the bloodstream, facilitating their transport to the immune system's central hubs. The goal is to generate a robust and durable immune response by activating and amplifying cancer-fighting T cells. Elicio's pipeline focuses on aggressive cancers, with a lead program in pancreatic ductal adenocarcinoma (PDAC).

Recent filings

Filing Released Lang Actions
EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer)
Regulatory Filings
2026-03-17 English
S-3/A - ELICIO THERAPEUTICS, INC. (0001601485) (Filer)
Registration Form
2026-03-02 English
S-3 - ELICIO THERAPEUTICS, INC. (0001601485) (Filer)
Registration Form
2026-02-27 English
4 Filing
Director's Dealing
2026-02-03 English
4 Filing
Director's Dealing
2026-02-03 English
4 Filing
Director's Dealing
2026-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.